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The cyclic nonapeptide arginine vasopressin (AVP) is synthesised
centrally mainly in the paraventricular nucleus (PVN) and the
supraoptic nucleus of the hypothalamus. Speciﬁc neuronal popu-
lations within the PVN can be subdivided into magnocellular and
parvocellular neurones based on their organisation and function.
Magnocellular neurones project to the posterior lobe of the pitu-
itary gland where they release AVP and the structurally related
peptide oxytocin into the bloodstream in response to physiologi-
cal stimuli, including hypovolaemia or elevated blood sodium
levels following haemorrhage or dehydration. Neuroendocrine
parvocellular neurones project to the external zone of the med-
ian eminence where AVP enters the hypophysial portal circulation
and is transported to the anterior lobe of the pituitary (1). Here,
AVP together with corticotrophin-releasing hormone (CRH) modu-
lates the secretion of adrenocorticotrophic hormone (ACTH) from
pituitary corticotrophs into the peripheral blood supply as part
of the response to stress by the hypothalamic-pituitary-adrenal
(HPA) axis (1).
The actions of AVP are mediated through a family of closely
related G protein-coupled receptors, which have been deﬁned by
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Arginine vasopressin (AVP) synthesised in the parvocellular region of the hypothalamic paraven-
tricular nucleus and released into the pituitary portal vessels acts on the 1b receptor subtype
(Avpr1b) present in anterior pituitary corticotrophs to modulate the release of adrenocorticotro-
phic hormone (ACTH). Corticotrophin-releasing hormone is considered the major drive behind
ACTH release; however, its action is augmented synergistically by AVP. To determine the extent of
vasopressinergic inﬂuence in the hypothalamic-pituitary-adrenal axis response to restraint and
forced swimming stress, we compared the stress hormone levels [plasma ACTH in both stressors
and corticosterone (CORT) in restraint stress only] following acute stress in mutant Avpr1b knock-
out (KO) mice compared to their wild-type controls following the administration of a novel
Avpr1b antagonist. Restraint and forced swimming stress-induced increases in plasma ACTH were
signiﬁcantly diminished in mice lacking a functional Avpr1b and in wild-type mice that had been
pre-treated with Avpr1b antagonist. A corresponding decrease in plasma CORT levels was also
observed in acute restraint-stressed knockout male mice, and in Avpr1b-antagonist-treated male
wild-type mice. By contrast, plasma CORT levels were not reduced in acutely restraint-stressed
female knockout animals, or in female wild-type animals pre-treated with Avpr1b antagonist.
These results demonstrate that pharmacological antagonism or inactivation of Avpr1b causes a
reduction in the hypothalamic-pituitary-adrenal (HPA) axis response, particularly ACTH, to acute
restraint and forced swimming stress, and show that Avpr1b knockout mice constitute a model
by which to study the contribution of Avpr1b to the HPA axis response to acute stressors.
Key words: acute stress, vasopressin, Avpr1b receptor antagonist, hypothalamic-pituitary-adre-
nal axis.
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proﬁles: AVP receptor subtype 1a (Avpr1a), Avpr1b and Avpr2.
Avpr1a is present in vascular smooth muscle and is responsible for
the classical vasopressor action of AVP (2) and has many putative
central roles (3–6); Avpr1b is primarily found in pituitary cortico-
trophs and modulates ACTH release, whereas Avpr2 controls water
resorbtion in renal collecting ducts (7).
In response to a variety of homeostatic challenges, the HPA axis
is activated as part of a complex endocrine and autonomic effort
to control changes in the homeostatic environment. Various brain
regions are activated as a result of such challenges, leading to a
consolidated response from the PVN (8–10). Parvocellular ACTH se-
cretagogues, AVP and CRH, act synergistically to promote ACTH
release from the anterior pituitary gland. ACTH stimulates a rapid
rise in blood glucocorticoid levels [cortisol in humans, corticoste-
rone (CORT) in rodents]. There is evidence that magnocellular-
derived AVP also participates in the control of ACTH release sug-
gesting a direct inﬂuence of the hypothalamic neurohypophysial
system on HPA axis function (1, 11). Glucocorticoids act on gluco-
corticoid receptors that are present in virtually all cells, to help
control alterations in the homeostatic environment as a result of
stress and also provide negative feedback at the pituitary, hypothal-
amus and higher brain centres. This ensures the stress response is
transient by turning off activated systems once the stressor has
ceased (12), preventing conditions associated with hypercortisolism.
In unstressed rats, approximately half of CRH-expressing parvocel-
lular neurones also express AVP, as measured by immunohisto-
chemistry (13) and a large number of studies have shown that AVP
plays a role, albeit perhaps minor compared to CRH, in the HPA
axis response to the majority of acute stressors. With the discovery
of ligands to pharmacologically manipulate Avpr1b (14–17), and the
construction of Avpr1b knockout (KO) mice (18, 19), there is a
growing impetus to investigate the contribution of Avpr1b to the
HPA axis response to acute and chronic (or repeated) stressors. Our
previous studies with Avpr1b KO mice revealed that Avpr1b is
required for a normal HPA axis response to a variety of acute stres-
sors [e.g. insulin-induced hypoglycaemia, lipopolysaccharide (LPS)
and ethanol challenge (20, 21)]. In the present study we extend
these observations to establish the role of Avpr1b in acute restraint
and forced swimming stress using Avpr1b KO mice in conjunction
with mice treated with a novel Avpr1b antagonist, Org (17).
Materials and methods
Animals
Adult (8–12 weeks old) mice (mix of C57BL⁄6J and 129 · 1⁄SvJ strains)
(18) were group housed and maintained under a 12 : 12 h light⁄dark cycle
(lights on 07.00 h) with controlled humidity (50%  5%) at 21  2  C,
with food and water available ad lib. Age-matched Avpr1b KO and wild-
type male and female littermates resulting from heterozygous parental
crosses ( for the Avpr1b mutation) were single housed 24 h before
experimentation to facilitate injection and experimentation procedures. All
female mice were used at random stages of the oestrous cycle. Animal
experiments were performed between 08.00 and 14.00 h in accordance
with Home Ofﬁce regulations described by the UK Animals (Scientiﬁc
Procedures) Act 1986, and were approved by the appropriate Bristol Uni-
versity Ethical Review Group.
Acute restraint stress
Restrained mice were placed in a 50-ml plastic Falcon tube for 30 min
before rapid decapitation. The tubes had up to ten small (approximately
5 mm) holes drilled around the sides of the tube and at its base to allow
for sufﬁcient ventilation. Control mice were brieﬂy handled and returned to
their home cage for 30 min before being killed. Restrained and handled mice
were pre-treated with Avpr1b antagonist or sterile water as detailed below,
with each experimental group containing ﬁve to seven mice. A previous
study (22) has shown that a 30-min time point is suitable to assess both
plasma ACTH and CORT hormone levels with this particular mild restraint
stress.
Acute forced swimming stress
Mice were placed in large glass beakers (1000⁄34D 5l, diameter 17 cm,
height 27 cm; Bibby Sterilin, Stoke, Staffordshire, UK) ﬁlled to a depth of
15 cm with water (22  2  C) for 5 min then rapidly decapitated. Mice in
control groups were handled brieﬂy, returned to their home cage for 5 min,
and then killed. As in the acute restraint experiment, mice were pre-treated
with Avpr1b antagonist or vehicle, with each experimental group containing
six to eight mice. Peak HPA axis activation after forced swimming stress,
denoted by ACTH levels, was previously observed (22) immediately following
stress, and hence was the time point chosen for this experiment. We have
not reported CORT measurements in the present study because we do not
know whether the single time point chosen would correspond to peak CORT
levels and were unable to include additional time points as a result of con-
straints in animal numbers from our breeding colony. Tanoue et al. (19)
working on another Avpr1b KO colony found that the ACTH response to
forced swimming in Avpr1b KO and wild-type mice was not profoundly dif-
ferent between 2 and 10 min of continual stress, whereas CORT levels fol-
lowing 4 min of forced swimming were signiﬁcantly lower than those
obtained after 10 min of forced swimming in Avpr1b wild-type animals.
Antagonist pre-treatment
Animals were pre-treated with either novel Avpr1b antagonist (Org) (17) or
sterile nonpyrogenic water (vehicle). Doses of Org used were based on previ-
ous studies using the same compound (23, 24). Org solutions were freshly
prepared on the day of injection in vehicle at doses of 10 and 30 mg⁄kg
for restraint experiments; on the basis of the efﬁcacy of these doses in this
paradigm, we lowered the Org doses to 1, 3 and 10 mg⁄kg for forced swim-
ming stress experiments. Animals were weighed the afternoon before experi-
mentation and doses were calculated accordingly. Mice were injected with
no more than 200 ll injection volume s.c. 2 h before commencing the stres-
sor. Pre-treatment with Org or vehicle 2 h before stress is consistent with
the time course of pre-treatment observed in a study by Craighead et al.
(17); however, this differs from the time course given of 30 min in studies
by Spiga et al. in rats (23, 24). We decided to pre-treat animals 2 h preced-
ing the stressor, aiming to minimise the inﬂuence of injection stress in our
animals, and to allow a more thorough absorption⁄uptake of antagonist
into blood and tissues before excretion or blood clearance.
Hormone analysis
Plasma obtained from the heparinised trunk blood of each animal was
stored at )20  C until analysis of ACTH and CORT concentrations by
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immunoassay kits (IDS, Tyne and Wear, UK), respectively. Each plasma
sample was analysed in duplicate and all absorbance readings were
performed at 450 nm with a Molecular Devices Versamax plate reader
(Molecular Devices Corporation, Sunnyvale, CA, USA). All ACTH and CORT
data are expressed as the mean  SEM of each group and were analysed
by three-way ANOVA followed by a Tukey’s honestly signiﬁcance difference
post-hoc test using SPSS, version 18 (SPSS Inc., Chicago, IL, USA). P < 0.05
was considered statistically signiﬁcant.
Results
The effect of Org on the HPA axis response to acute
restraint stress
In the ﬁrst set of experiments, wild-type and KO mice received s.c.
injections of 10 and 30 mg⁄kg Org Avpr1b antagonist or vehicle
before 30 min of restraint stress. Restraint increased the HPA axis
hormone response in male and female wild-type mice (Fig. 1). Male
plasma ACTH levels rose four-fold in wild-type stressed animals
compared to the wild-type handled group (Fig. 1A: n = 5–7,
P < 0.0001) and plasma CORT levels increased > 14-fold following
stress in wild-type animals compared to the corresponding handled
controls (Fig. 1B: n = 5–7, P < 0.0001). Such increases in ACTH and
CORT response to restraint were also observed in female mice
(Fig. 1C,D). Handled wild-type and KO mice in vehicle-treated, con-
trol groups had similarly low plasma ACTH and CORT levels.
Although there was no signiﬁcant increase in the ACTH response in
either male or female Avpr1b KO mice subjected to restraint, the
CORT response was signiﬁcantly elevated (approximately 600 and
300% increase for males and females, respectively) compared to KO
handled controls in male and female experiments (Fig. 1C,D). The
plasma ACTH and CORT elevation in response to restraint found in
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Fig. 1. Plasma hormone responses to 30 min restraint stress after subcutaneous injection of 10 or 30 mg⁄kg Org or vehicle 2 h before the onset of stress in
male (A, B) and female (C, D) wild-type (+⁄+) and arginine vasopressin receptor subtype 1a (Avpr1a) knockout (KO) ()⁄)) mice. All values are the mean  SEM
(n = 5–8 animals per group). Signiﬁcance is denoted as: *P < 0.05–0.01, **P < 0.01–0.001, ***P < 0.001; NS, not signiﬁcant. Wild-type plasma adrenocorticotro-
phic hormone (ACTH) levels (A, C) rose signiﬁcantly in response to restraint stress versus handled controls in male and female mice. This rise in ACTH is
reﬂected in the corticosterone (CORT) responses (B, D). Avpr1b KO plasma hormone levels also rose in response to restraint stress, with a marginally signiﬁcant
difference in ACTH data and a highly signiﬁcant difference in CORT data versus vehicle treated, handled Avpr1b KO controls. Male and female Avpr1b KO mice
had a considerably reduced ACTH and CORT response to restraint stress compared to wild-type mice subjected to the same treatment. Org injection signiﬁ-
cantly attenuated the stress-induced rise in ACTH at both 10 and 30 mg⁄kg doses in male and female experiments.
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that observed in wild-type mice (ACTH, n = 7, P < 0.0001; CORT,
n = 7, P < 0.0001). In female mice, the ACTH, but not CORT,
response to restraint was attenuated in KO animals (ACTH levels
decreased by 60%).
Injection of Avpr1b antagonist 2 h before the onset of 30 min of
restraint had a profound effect on the stress-induced increase in
plasma ACTH levels in male and female mice. The ACTH response to
stress was reduced by 70% in wild-type male mice after pre-treat-
ment with both 10 and 30 mg⁄kg antagonist (Fig. 1A;n = 7 ,
P < 0.0001 at both doses). This trend was also observed in female
mice (Fig. 1C), with Org reducing the stress-induced ACTH increase
by approximately 70% at the two doses used (n = 6–7, P < 0.0001
at 10 and 30 mg⁄kg). This was not strictly matched in the plasma
CORT responses to restraint stress because only male stress-induced
CORT responses after antagonist pre-treatment were signiﬁcantly
reduced after antagonism; a decrease of 25% and 36% was seen
at 10 and 30 mg⁄kg compared to vehicle treated wild-types,
respectively (n = 7, P < 0.05 at 10 mg⁄kg and P < 0.0001 at
30 mg⁄kg; Fig. 1B).
Interestingly, restrained wild-type males and females pre-treated
with Org (at both doses) show a reduction in plasma ACTH to
levels approaching those observed in handled control mice. Fol-
lowing restraint, male and female KO plasma ACTH levels remain
unchanged after Org pre-treatment (both doses) compared to
vehicle-injected, restrained KO mice. This suggests that Org treat-
ment has no antagonist activity on KO animals. Plasma ACTH lev-
els in Org pre-treated, restrained wild-type mice duplicated that
of the KO counterparts, indicating that the effect of Org closely
corresponds to that of Avpr1b inactivation. The reduction of
stress-induced plasma ACTH secretion to basal levels after injec-
tion with Org seen in the male and female ACTH data was not
paralleled in the male or female CORT results, with wild-type
restraint groups all being signiﬁcantly higher compared to handled
controls.
The effect of Org on the HPA axis response to acute forced
swimming stress
The results obtained with respect to the peripheral injection of 1,
3 and 10 mg⁄kg Org, administered 2 h before 5 min of forced
swimming in male and female Avpr1b wild-type and KO mice are
shown in Fig. 2. Plasma from trunk blood collected immediately
after swimming showed a rapid rise in wild-type mice plasma
ACTH levels. Male vehicle-treated, wild-type control mice had
plasma ACTH levels that increased 1.8-fold after swimming stress
(Fig. 2A, n = 6, P < 0.05). Forced swimming also increased plasma
ACTH levels in wild-type female mice compared to handled con-
trols (Fig. 2B).
Avpr1b KO mice exhibit no increase in ACTH after forced swim-
ming; the male and female KO ACTH response to stress were 71%
and 75% lower than that of wild-type mice, respectively [males,
Fig. 2A: Org injection at doses of 1 and 3 mg⁄kg attenuated swim-
ming stress-induced ACTH release in male wild-type mice, reducing
plasma ACTH by 56% (1 mg⁄kg, n = 6–8, P < 0.0001) and 65%
(3 mg⁄kg, n = 6–8, P < 0.0001) with respect to vehicle-treated
wild-type mice]. Interestingly, the reduction in plasma ACTH in
wild-type, stressed mice seen after pre-treatment with 10 mg⁄kg
failed to achieve signiﬁcance, whereas the reduction following
lower doses was signiﬁcantly different. We observed a similar
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Fig. 2. Plasma adrenocorticotrophic hormone (ACTH) responses to 5 min of forced swimming stress (FS) after subcutaneous injection of 1, 3 or 10 mg⁄kg
Org or vehicle 2 h before the onset of stress in male (A) and female (B) wild-type (+⁄+) and arginine vasopressin receptor subtype 1a (AVpr1a) knockout (KO)
()⁄)) mice. All values are the mean  SEM (n = 6–8 animals per group). Signiﬁcance is denoted as: *P < 0.05–0.01, **P < 0.01–0.001 ***P < 0.001; NS, not
signiﬁcant. The forced swimming stress signiﬁcantly elevated plasma ACTH levels in wild-type male and female mice with respect to handled control +⁄+ mice.
Avpr1b mutant males and females displayed a profoundly reduced ACTH response to acute forced swimming stress compared to their wild-type counterparts
in the same treatment group. Previous treatment of animals with 1 and 3 but not 10 mg⁄kg Org reduced male plasma ACTH levels to levels comparable with
handled control mice. An equivalent reduction in plasma ACTH was seen in female wild-types with Org pretreatment. In each treatment group injected with
Avpr1b antagonist, there was no signiﬁcant difference between wild-type and Avpr1b KO mice ACTH levels in male and female cohorts.
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injected female groups. Signiﬁcant reductions in swimming stress-
induced plasma ACTH levels were only noted after pre-treatment of
female wild-type mice with 1 and 10 mg⁄kg.
As observed in the restraint stress data, the antagonist had no
effect on KO plasma ACTH levels, which remained at the level of
vehicle-treated swimming stressed KOs. On the other hand, wild-
type mice pre-treated with Org had an attenuated ACTH response
to forced swimming: ACTH plasma levels were decreased to a level
similar to that for Org-treated stressed KO mice⁄vehicle-treated
handled KO mice, as well as vehicle-treated handled wild-type mice.
The magnitude of ACTH response to forced swimming was smal-
ler in stressed, wild-type female mice compared to the signiﬁcantly
larger response observed in similarly stressed male mice.
Discussion
The present study employed both genetic and pharmacological
manipulations to demonstrate that intact and functional Avpr1b
are needed to mount a normal HPA axis response to both acute
restraint and forced swimming stress. Previously, we have shown
that mice lacking functional Avpr1b have a reduced HPA axis
response to a number of ‘chemical’ or ‘physical-emotional’ stressors,
including acute LPS challenge, ethanol injection (21), acute mild
restraint, forced swimming stress, change of environment (22),
insulin-induced hypoglycaemia (20) and acute antidepressant
administration (25), compared to their wild-type counterparts.
Avpr1b mutant mice generated by another group also show a
reduced HPA axis response to acute forced swimming stress (19).
There are a number of studies using the Brattleboro rat, a naturally
occurring mutant strain lacking the ability to produce AVP, that
emphasise the importance of AVP in driving the ACTH response to
acute stress (26–30). The most recent of these studies (28) used
Brattleboro rats in a variety of stress paradigms and concluded that
the loss of AVP affects the HPA axis response to most (13 out of
18) of the stressors studied; there are speciﬁc stressors that exhibit
a reduction in both ACTH and CORT (e.g. restraint), a reduction in
ACTH only (e.g. forced swimming stress) and HPA stress responses
that are not inﬂuenced by the loss of AVP (e.g. footshock). CRH
levels remain unchanged in hypothalamic samples of unstressed
Brattleboro rats (31), and the profound reduction in ACTH plasma
levels following acute stress seen in this and our previous studies
(20–22, 25) demonstrate that the loss of Avpr1b cannot be
compensated for by CRH or other factors.
There is conﬂicting evidence with respect to the resting levels of
ACTH and CORT in Battleboro rats and Avpr1b KO mice, with some
studies reﬂecting reduced basal hormone levels [Brattleboro rats
(32–34); Avpr1b KO mice (19)], whereas others report no difference
[Brattleboro rats (26–30); Avpr1b KO mice (18) (CORT only)]. Our
own previous observations suggest basal ACTH⁄CORT levels in
Avpr1b KO mice are indistinguishable from wild-type levels, and we
attribute this ﬁnding to resting levels of CRH or other ACTH secret-
agogues that are sufﬁcient to maintain basal HPA axis activity. It is
important to note that, in Brattleboro rats and Avpr1b KO mice,
there may also be other ACTH secretagogues (e.g. oxytocin) released
atypically, or that are present at altered levels, that may compen-
sate for the loss of Avpr1b activity. Oxytocin which has a modest
efﬁcacy at Avpr1b is known to mediate ACTH release via Avpr1b
(35, 36). This may feature as a compensatory mechanism in the
Brattleboro rat, although it cannot compensate for the loss of
Avpr1b in mouse mutants in this manner, as a result of the loss of
Avpr1b itself rather than its cognate ligand. On the other hand, it
has been reported that oxytocin at high levels can activate oxytocin
receptors (Oxtr) present in pituitary corticotrophs to release ACTH
(37) and that oxytocin could actively release ACTH in Avpr1b KO
mice (37). Centrally administered oxytocin acting via the Oxtr
reduces stress-induced CORT release in rats (38), and has been
reported to exert anxiolytic effects in mice, possibly by modulating
serotonergic neurone activity (39). Thus, oxytocin may have oppos-
ing actions on HPA axis activity depending on whether it acts on
the central Oxtr or pituitary Avpr1b the activity of oxytocin at the
central Avpr1b is not known. Our results obtained in wild-type ani-
mals pre-treated with an Avpr1b antagonist show a pronounced
reduction in plasma ACTH after exposure to acute restraint and
forced swimming stressors. The doses of Org used in the restraint
(10 and 30 mg⁄kg) and forced swimming (1, 3 and 10 mg⁄kg)
experiments generally show a similar reduction in the stress-
induced ACTH release as a result of the effective blockade of
Avpr1b. Exceptions to this trend appear in wild-type male and
female mice exposed to swimming stress pre-treated with 10 and
3m g⁄kg of Avpr1b antagonist, respectively. These groups just fail
(P < 0.064) to achieve signiﬁcantly lower plasma ACTH levels fol-
lowing forced swimming stress compared to vehicle-treated coun-
terparts. The reason for these discrepancies are not clear; however,
in both cases, there is a trend for the plasma ACTH levels to be
lower than vehicle-treated swimming stressed animals and, indeed,
these groups would have been statistically signiﬁcant from their
vehicle-injected counterparts had they each not included one ‘out-
lier’ (from a sample number of eight and seven, for the male and
female groups, respectively), which had a value that was > 2 stan-
dard deviations away from the mean value. Antagonist administra-
tion in wild-type animals reduces the stress-induced ACTH release
to levels akin to the stressed Avpr1b KO animals. As expected, Org
injection in Avpr1b KO mice had no effect on stress-induced ACTH
levels compared to stressed, vehicle-treated mutants. The reduction
in ACTH levels after Org treatment in the present study is corrobo-
rated by ﬁndings observed with the antagonist in rats: ACTH levels
are reduced after acute restraint stress and LPS immune challenge
but not after noise stress (17, 23, 24). In keeping with the results
using Org, the Avpr1b selective nonpeptide antagonist SSR149415
has also been shown to attenuate the ACTH response to restraint
stress and ether exposure, yet the forced swimming, stress-induced
ACTH response is unaltered in rats (14, 40). The speciﬁcity of
SSR149415 has been questioned, with evidence of signiﬁcant
antagonism at the human Oxtr in addition to the human Avpr1b
CHO cell lines expressing the recombinant receptors being noted
(41). The high speciﬁcity of Org [human Avpr1b pKi 8.4 versus < 5
for all other human AVP receptors (17)] provides a precise tool, in
addition to Avpr1b KO mice, by which to study Avpr1b. Org is also
a highly effective Avpr1b antagonist in various rat models (17, 23,
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proﬁles of rat and mouse Avpr1b (42), and the use of Org in mice
has not been previously reported.
Our data on acute restraint highlight an apparent dissociation
between plasma ACTH and CORT levels, when comparing wild-type
versus Avpr1b KO mice or the vehicle treated wild-type versus Org
treated mice. The removal of the Avpr1b contribution to the HPA
axis response to acute stress by antagonist and genetic inactivation,
markedly reduces plasma ACTH levels, although it has a less pro-
nounced or marginal (if any, particularly in the case of our female
CORT data) effect on CORT levels. It is possible that, because we
only measured blood samples at a single time point, an incremental
change in plasma CORT levels may have been missed. Dissociation
between plasma pituitary ACTH and adrenal CORT secretions have
been found in a number of acute and chronic stress studies in
rodents (20, 22, 24, 26, 28, 43–45). Additionally, in analyses
employing serial blood sampling techniques in rats, ACTH and CORT
mismatches are often observed (24, 26, 28). Low levels of ACTH as
seen in stressed Avpr1b KO animals may be sufﬁcient to stimulate
a full CORT response from the adrenal. In addition, a number of
factors may inﬂuence adrenal glucocorticoid secretions (46) and it
is clear that ACTH-dependent and independent, neural and immune
variations inﬂuence adrenal sensitivity and glucocorticoid genesis or
release (46, 47). Elevated plasma CORT levels with low ACTH levels
as observed in the present study may also be a result of sympatho-
adrenomedullary modulation of adrenal cortex sensitivity to ACTH;
direct paracrine action or indirect reﬁnement of adrenal cortical
function by AVP on Avpr1a and Avpr1b (48) present in the adrenal
medulla (49) suggests that adrenal cortex and medulla secretions
may be inﬂuenced by the action of locally-produced AVP on the
Avpr1a.
It is well established that the nature and severity of each stres-
sor fundamentally alters how the HPA axis responds to each chal-
lenge, emphasising the complexity of how different stressors are
interpreted, and the impact of numerous other inﬂuencing systems
(e.g. immune activation) on HPA axis activation. Microarray data
examining the transcriptional proﬁles in response to different acute
stressors (LPS versus restraint stress in mice) (50) reveal that there
is apparently little overlap in PVN gene expression, suggesting fur-
ther scope for more detailed categorisation of stress effects by the
genes activated. With respect to AVP, there is no obvious correla-
tion between AVP inﬂuence (via Avpr1b activation) and speciﬁc
categories of stressor (28). However, there are certain instances
when the AVP system may drive the HPA axis; for example, Zelena
et al. (28) note two stressors, immune challenge and insulin-
induced hypoglycaemia, in which the contribution of the vaso-
pressinergic system to HPA axis response in rats appears to be
substantial. We have previously demonstrated the prominence of
AVP⁄Avpr1b in the plasma ACTH and CORT responses to acute
insulin-induced hypoglycaemia stress in mice (20). The restraint
stress procedure used in the present study is milder than one we
have previously employed (20) in which no difference was observed
in the ACTH and CORT responses to acute exposure. A weaker HPA
axis response to the less severe restraint stress permits the delin-
eation of the vasopressinergic component driving the ACTH release,
possibly because the salient ACTH secretagogue CRH, does not
over-ride the subtle effects of AVP. Interestingly, restraint stress
activates a number of immune-related molecules (e.g. interleukin-
13) that are not activated by LPS challenge in mice (50). The acti-
vation of dissimilar immune pathways in response to different
stressors may dynamically alter the HPA axis ACTH and CORT
secretion proﬁles.
In the present study, we have noted some gender differences in
the ACTH responses to acute restraint and forced swimming in
wild-type mice (e.g. restraint-induced ACTH levels following Org
pre-treatment are lower in males; the ACTH response to forced
swimming is smaller in females). Because we did not examine ACTH
or CORT levels at different stages of the oestrous cycle, we are
unable to attribute such gender differences to changes in circulat-
ing sex steroids. However, gender differences in HPA axis regulation
are not uncommon [in humans, females tend to display higher
activity than males (51)], although this may be dependent on the
nature of the stress (52) and, in rodents, such differences may be
associated with the effects of sex steroids on AVP, oxytocin or CRH
gene expression in the PVN (53, 54).
The rodent Avpr1b is found principally in anterior pituitary corti-
cotrophs but is also detected in adrenal glands and the brain (55–
58). The site at which Org impacts on ACTH secretion is likely to be
the pituitary, although antagonism of central Avpr1b may also con-
tribute to the overall effect of Org on the HPA axis response to
acute stressors. Although Org has a relatively low brain penetration
(17), we do not know the concentrations of antagonist that may be
active at central sites in vivo. Avpr1b mRNA is present in brain
regions that directly and indirectly innervate the PVN, such as the
hippocampus and amygdala, and indeed the PVN itself (58).
Although caution must be used when interpreting mRNA levels and
extrapolating them to protein expression, the central Avpr1b gene
expression leaves open the possibility that Avpr1b in higher brain
centres that interpret speciﬁc pathways may modulate PVN activity.
Intracerebroventricular injection of Org, or brain-region speciﬁc
Avpr1b KOs⁄knockdowns, would likely demonstrate any potential
effect of central Avpr1b.
We conclude that the elimination of vasopressinergic activity at
Avpr1b either by genetic inactivation or pharmacological antago-
nism, results in an attenuated ACTH response to acute restraint and
forced swimming stress. Comparable results produced by both
Avpr1b KO and Org pre-treatment suggest that Org is a useful tool
by which to further investigate the role of Avpr1b in vivo. Our
results also highlight that Avpr1b KO mice used in our studies are
unlikely to have developed substantial compensatory mechanisms
to adjust for the loss of Avpr1b.
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